Stivarga is a medicinal drug composed of Regorafenib as the main active component. This medicine is indicated for the treatment of colorectal cancer and liver cancer. This medicine is a cancer growth blocker manufactured by leading pharmaceutical companies, Bayer HealthCare Pharmaceuticals Inc. It has been offered in a conventional tablet form in a dosage of 40 mg.
Manufacturer: Bayer HealthCare Pharmaceuticals Inc.
Active Ingredient: Regorafenib is the main active ingredient in this mediation. It shows potential antiangiogenic and antineoplastic activities. This active component binds to and inhibits vascular endothelial growth factor receptors 2 and 3, and Ret, Kit, PDGFR and Raf kinases. It leads to the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that are essentials in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, as well as the serine/threonine-specific Raf kinase, are involved in tumor cell signaling.
Indications: This medicine is composed of regorafenib as the active component, which is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Stivarga is approved for the treatment of colorectal cancer and liver cancer. This medication is also indicated to treat a rare type of tumor that can affect the esophagus, stomach, or intestines.
Action Mechanism: This mentioned medicine is a type of targeted cancer drug called a cancer growth blocker. Stivarga works in two ways. It restricts the signals that instruct cancer cells to grow and cancer cells forming new blood vessels, which they need to be able to grow.
Dosages: This cancer-treating medicine is made available for oral administration in a dosage as given below:
- 40 mg: It is to be consumed once a day for 21 days with a low-fat meal as directed by the doctor
Note: This drug can harm the liver. Do not take this medicine and seek the doctor’s advice at once it causes nausea, vomiting, sleep problems, dark urine, or jaundice.